Speaker(s): 

Maria Fioti, PharmD Candidate 2026, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1.  Describe the limitations of oral anticoagulation (OAC) in atrial fibrillation 
   (AFib), including intolerance, contraindications, and real-world barriers to 
   use
2. Explain the clinical rationale for non-pharmacologic stroke-prevention in 
   AF patients who cannot take OAC
3. Identify appropriate patient populations who may benefit from left atrial 
   appendage closure (LAAC)
4. Compare key evidence from major studies evaluating LAAC devices such 
   as WATCHMAN®
5. Apply evidence-based decision-making to select a stroke-prevention 
   strategy for an AFib patient unable to tolerate long-term anticoagulation

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.